Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
UCB5857
DRUG
2 trials
Sponsors
UCB Celltech
Conditions
Healthy Volunteers
Primary Sjögren's Syndrome
Phase 1
Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of UCB5857 in Healthy Subjects
Completed
NCT02207595
UCB Celltech
Healthy Volunteers
Start: 2014-08-31
End: 2015-02-28
Updated: 2015-03-05
Phase 2
UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome
Terminated
NCT02610543
UCB Celltech
Primary Sjögren's Syndrome
Start: 2015-10-31
End: 2017-12-05
Updated: 2020-12-01
Related Papers
A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren’s syndrome
Lara D. Veeken
2020-08-27
42 citations
First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases.
2017-02-04
15 citations